Edwards Lifesciences Corporation (EW) Shares Bought by Artisan Partners Limited Partnership
Artisan Partners Limited Partnership increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 12.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,432,428 shares of the medical research company’s stock after purchasing an additional 153,896 shares during the period. Artisan Partners Limited Partnership owned approximately 0.68% of Edwards Lifesciences worth $156,579,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ boosted its position in shares of Edwards Lifesciences by 163.7% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 94,710 shares of the medical research company’s stock worth $10,353,000 after purchasing an additional 58,800 shares during the period. KBC Group NV boosted its position in shares of Edwards Lifesciences by 19.1% during the 3rd quarter. KBC Group NV now owns 116,945 shares of the medical research company’s stock worth $12,783,000 after purchasing an additional 18,742 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Edwards Lifesciences by 0.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 593,513 shares of the medical research company’s stock worth $64,875,000 after purchasing an additional 1,660 shares during the period. Hillsdale Investment Management Inc. boosted its position in shares of Edwards Lifesciences by 43.5% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 3,300 shares of the medical research company’s stock worth $361,000 after purchasing an additional 1,000 shares during the period. Finally, Tiedemann Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 18.2% during the 3rd quarter. Tiedemann Wealth Management LLC now owns 42,297 shares of the medical research company’s stock worth $1,083,000 after purchasing an additional 6,498 shares during the period. 81.55% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the sale, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00. The disclosure for this sale can be found here. Insiders sold a total of 172,480 shares of company stock worth $18,548,810 over the last 90 days. Company insiders own 2.13% of the company’s stock.
A number of equities analysts recently weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday. Deutsche Bank lowered their price objective on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Morgan Stanley reduced their target price on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a report on Thursday, October 26th. Barclays reduced their target price on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 25th. Finally, SunTrust Banks set a $124.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences has a consensus rating of “Buy” and a consensus target price of $125.53.
Shares of Edwards Lifesciences Corporation (NYSE EW) opened at $116.41 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $81.25 and a fifty-two week high of $121.45. The stock has a market cap of $24,801.85, a P/E ratio of 32.47, a price-to-earnings-growth ratio of 2.10 and a beta of 0.50. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the previous year, the business posted $0.68 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. equities analysts predict that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corporation (EW) Shares Bought by Artisan Partners Limited Partnership” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/02/edwards-lifesciences-corporation-ew-shares-bought-by-artisan-partners-limited-partnership.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.